M
Matthew J. Matasar
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 197
Citations - 4310
Matthew J. Matasar is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 141 publications receiving 2982 citations. Previous affiliations of Matthew J. Matasar include Cornell University.
Papers
More filters
Journal ArticleDOI
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn,Alex F. Herrera,Christopher R. Flowers,Manali Kamdar,Andrew McMillan,Mark Hertzberg,Sarit Assouline,Tae Min Kim,Won Seog Kim,Muhit Ozcan,Jamie Hirata,Elicia Penuel,Joseph N. Paulson,Ji Cheng,Grace Ku,Matthew J. Matasar +15 more
TL;DR: Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.
Journal ArticleDOI
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Antonio Omuro,Denise D. Correa,Lisa M. DeAngelis,Craig H. Moskowitz,Matthew J. Matasar,Thomas Kaley,Igor T. Gavrilovic,Craig Nolan,Elena Pentsova,Christian Grommes,Katherine S. Panageas,Raymond E. Baser,Geraldine Faivre,Lauren E. Abrey,Craig S. Sauter +14 more
TL;DR: This high-dose chemotherapy with autologous stem-cell transplant with HDC-ASCT was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far.
Journal ArticleDOI
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz,Matthew J. Matasar,Andrew D. Zelenetz,Stephen D. Nimer,John F. Gerecitano,Paul A. Hamlin,Steven M. Horwitz,Alison J. Moskowitz,Ariela Noy,Lia Palomba,Miguel-Angel Perales,Carol S. Portlock,David J. Straus,Jocelyn C. Maragulia,Heiko Schöder,Joachim Yahalom +15 more
TL;DR: Evidence is provided that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT, and a risk-adapted approach to improve PFS after high-dose radio-chemotherapy (HDT) and ASCT is used.
Journal ArticleDOI
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz,Heiko Schöder,Joachim Yahalom,Susan J. McCall,Stephanie Y. Fox,John F. Gerecitano,Ravinder K. Grewal,Paul A. Hamlin,Steven M. Horwitz,Rachel Kobos,Anita Kumar,Matthew J. Matasar,Ariela Noy,M. Lia Palomba,Miguel-Angel Perales,Carol S. Portlock,Craig S. Sauter,Neerav Shukla,Peter G. Steinherz,David J. Straus,Tanya M. Trippett,Anas Younes,Andrew D. Zelenetz,Craig H. Moskowitz +23 more
TL;DR: In this article, the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE) were assessed.
Journal ArticleDOI
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Alison J. Moskowitz,Paul A. Hamlin,Miguel-Angel Perales,John F. Gerecitano,Steven M. Horwitz,Matthew J. Matasar,Ariela Noy,Maria Lia Palomba,Carol S. Portlock,David J. Straus,Tricia Graustein,Andrew D. Zelenetz,Craig H. Moskowitz +12 more
TL;DR: This phase II study confirms the efficacy of bendamustine in heavily pretreated patients with HL and supports current and future studies evaluating bendamUSTine combinations in relapsed and refractory HL.